See more : Takatori Corporation (6338.T) Income Statement Analysis – Financial Results
Complete financial analysis of Avidity Biosciences, Inc. (RNA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avidity Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Pathfinder Ventures Inc. (RV.V) Income Statement Analysis – Financial Results
- Gansu Guofang Industry & Trade (Group) Co., Ltd. (601086.SS) Income Statement Analysis – Financial Results
- Sincerity Applied Materials Holdings Corp. (SINC) Income Statement Analysis – Financial Results
- Nitto Denko Corporation (6988.T) Income Statement Analysis – Financial Results
- Ocean Outdoor Limited (OOUT.L) Income Statement Analysis – Financial Results
Avidity Biosciences, Inc. (RNA)
About Avidity Biosciences, Inc.
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 9.56M | 9.22M | 9.33M | 6.79M | 2.32M | 379.00K |
| Cost of Revenue | 2.10M | 1.39M | 639.00K | 37.60M | 14.54M | 8.44M |
| Gross Profit | 7.46M | 7.84M | 8.69M | -30.82M | -12.22M | -8.06M |
| Gross Profit Ratio | 78.02% | 84.96% | 93.15% | -454.03% | -526.95% | -2,125.86% |
| Research & Development | 190.97M | 150.40M | 101.18M | 37.60M | 14.54M | 8.44M |
| General & Administrative | 54.19M | 37.73M | 26.20M | 13.46M | 5.11M | 2.44M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 54.19M | 37.73M | 26.20M | 13.46M | 5.11M | 2.44M |
| Other Expenses | 0.00 | 4.92M | 42.00K | -78.00K | 0.00 | 0.00 |
| Operating Expenses | 245.16M | 188.14M | 127.38M | 51.06M | 19.65M | 10.88M |
| Cost & Expenses | 245.16M | 188.14M | 127.38M | 51.06M | 19.65M | 10.88M |
| Interest Income | 23.97M | 4.98M | 104.00K | 206.00K | 7.39M | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 209.00K | 7.39M | 718.00K |
| Depreciation & Amortization | 2.10M | 1.39M | 639.00K | 373.00K | 597.00K | 383.00K |
| EBITDA | -233.50M | -177.53M | -117.41M | -43.77M | -16.75M | -10.12M |
| EBITDA Ratio | -2,442.44% | -1,939.65% | -1,265.83% | -652.38% | -732.38% | -2,668.87% |
| Operating Income | -235.60M | -178.91M | -118.05M | -44.28M | -17.33M | -10.50M |
| Operating Income Ratio | -2,464.41% | -1,939.65% | -1,265.83% | -652.38% | -747.39% | -2,769.92% |
| Total Other Income/Expenses | 23.38M | 4.92M | 42.00K | -78.00K | -7.40M | -718.00K |
| Income Before Tax | -212.22M | -174.00M | -118.01M | -44.36M | -24.73M | -11.22M |
| Income Before Tax Ratio | -2,219.87% | -1,886.33% | -1,265.38% | -653.53% | -1,066.58% | -2,959.37% |
| Income Tax Expense | 0.00 | -4.92M | -639.00K | -373.00K | 7.39M | 718.00K |
| Net Income | -212.22M | -169.08M | -117.37M | -43.98M | -32.12M | -11.93M |
| Net Income Ratio | -2,219.87% | -1,833.01% | -1,258.52% | -648.03% | -1,385.12% | -3,148.81% |
| EPS | -2.91 | -3.24 | -2.83 | -2.03 | -0.86 | -0.58 |
| EPS Diluted | -2.91 | -3.24 | -2.83 | -2.03 | -0.86 | -0.58 |
| Weighted Avg Shares Out | 73.01M | 52.16M | 41.43M | 21.66M | 37.51M | 20.68M |
| Weighted Avg Shares Out (Dil) | 73.01M | 52.16M | 41.43M | 21.66M | 37.51M | 20.68M |
Avidity Biosciences to Participate in Upcoming Investor Conference
SAN DIEGO , Nov. 26, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the...
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Nov. 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on November 20, 2024, the Human Capital Management Committee of...
RNA Stock Hits Record High on Entering the Cardiac Disease Space
Avidity Biosciences expands its pipeline to include two new drugs targeting rare genetic cardiomyopathies.
Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News
Shares of Avidity Biosciences surged to a record high Wednesday after the company showed its hand in the cardiovascular space. The post Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News appeared first on Investor's...
Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations
Avidity expands its leading RNA delivery technology into precision cardiology with two new wholly-owned development candidates targeting rare genetic cardiomyopathies: AOC 1086 to treat PLN Cardiomyopathy and AOC 1072 to treat PRKAG2 Syndrome AOC 1072 and AOC 1086 preclinical data...
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Lags Revenue Estimates
Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.71 per share a year ago.
Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights
Enrollment in global Phase 3 HARBOR™ study for del-desiran in DM1 is on track Avidity initiated biomarker cohort for del-brax FORTITUDE™ study for FSHD; pursuing a potential accelerated approval path for del-brax Reported positive del-zota data from Phase 1/2 EXPLORE44™...
Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for
Avidity Biosciences (RNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024
Avidity to present poster on precision cardiology candidate at American Heart Association (AHA) Scientific Sessions 2024 taking place November 16-18, 2024 Volume 11 of investor and analyst event series will be available via webcast November 12, 2024, at 8:00 a.m....
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Oct. 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on October 20, 2024, the Human Capital Management Committee...
Source: https://incomestatements.info
Category: Stock Reports